Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-ITNK
- Development stage
- Phase 2
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Based on available information, CAR-ITNK appears to be related to chimeric antigen receptor (CAR) cellular immunotherapy. CAR therapies involve genetically modifying immune cells to express receptors that target specific antigens on cancer cells. However, specific details about CAR-ITNK's mechanism of action, development status, and clinical applications are not available in the provided search results.
- Other names
- Induced-T cell-like NK cellsinduced T-to-NK cellsiTNK cells
Beyond the preview
Go deeper on CAR-ITNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-ITNK.